There is a mega trend on social media of people discussing microdosing Ozempic, Wegovy and GLP-1 medications.  Some experts suggest microdosing is better for patients because the prescribed doses are over medicating patients. What are the pros and cons of microdosing?

GLP-1 Microdosing: Trends, Evidence, and Safety Concerns

We explore the emerging trend of microdosing GLP-1 receptor agonists, such as semaglutide and tirzepatide, which are typically prescribed for diabetes and weight loss. Microdosing refers to using significantly smaller doses than the standard therapeutic amounts, often motivated by cost savings, a desire to minimize side effects, and accessibility during shortages. While anecdotal reports suggest potential benefits, the sources emphasize the lack of scientific evidence and potential risks associated with this practice, including reduced efficacy and safety concerns, especially with compounded versions. Expert opinions and regulatory bodies generally advise caution against microdosing due to the absence of robust clinical data and the availability of approved dosing regimens. Ultimately, the texts highlight the importance of evidence-based medical guidance over unproven off-label use of these powerful medications.

This is the official podcast of GLP-1 Tribe. Find out more at https://glp1tribe.com/